Side-by-side comparison of AI visibility scores, market position, and capabilities
Waystar is a healthcare payments and revenue cycle technology platform processing over $5 trillion in claims annually for hospitals, health systems, and physician groups.
Waystar is a healthcare technology company formed through the 2019 merger of ZirMed and Navicure that provides cloud-based revenue cycle management technology to healthcare providers. The platform automates the complex workflows involved in healthcare payments including eligibility verification, claims submission, denial management, payment posting, and patient payment collection. Waystar processes over $5 trillion in annual claims for a network of over 1,000 health plan and payer connections, making it one of the largest healthcare clearinghouse and RCM technology providers in the United States. The company serves hospitals, health systems, physician practices, and ancillary care providers of all sizes through a SaaS platform that integrates with major EHR systems. Waystar went public on Nasdaq in 2024 following years of private equity ownership under EQT Partners. The company uses AI to improve claim accuracy before submission, prioritize denial appeals, and automate patient payment workflows. Waystar's scale and network of payer connections make it a critical piece of healthcare financial infrastructure for providers seeking to improve cash flow and reduce administrative costs.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.